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Hepatocellular carcinoma (HCC) is an increasingly common indication for liver trans-
plantation (LT) in the United States and in many parts of the world. In the last decade, 
significant work has been done to better understand how to risk stratify LT candi-
dates for recurrence of HCC following transplant using a combination of biomarker 
and imaging findings. However, despite the high frequency of HCC in the LT popula-
tion, guidance regarding posttransplant management is lacking. In particular, there 
is no current evidence to support specific post-LT surveillance strategies, leading to 
significant heterogeneity in practices. In addition, there are no current recommen-
dations regarding recurrence prevention, including immunosuppression regimen or 
secondary prevention with adjuvant chemotherapy. Finally, guidance on treatment 
of disease recurrence is also lacking and there is significant controversy about the 
use of immunotherapy in transplant recipients due to the risk of rejection. Thus, out-
comes for patients with recurrence are poor. This paper therefore provides a com-
prehensive review of the current literature on post-LT management of patients with 
HCC and identifies gaps in our current knowledge that are in urgent need of further 
investigation.
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1  | INTRODUC TION
In this era of rising hepatocellular carcinoma (HCC) incidence, HCC 
is an increasingly common indication for liver transplantation (LT). In 
2015, HCC was the indication for 24% of liver transplant registrants 
and 27% of liver transplants, rendering it the most common reason 
for LT and waitlist additions, regardless of underlying etiology.1
LT began to evolve as a therapy for HCC when the incidental 
finding of small HCC in explanted livers was not found to alter out-
comes as compared to explants without HCC.2 The landmark study 
by Mazzaferro in 1996 then established LT as an effective treatment 
for early HCC defined by the Milan Criteria (one lesion ≤5 cm or 3 le-
sions all ≤3 cm without evidence of vascular invasion or extrahepatic 
spread).3 Survival following LT for HCC has improved over time with 
advances in care and is similar to that of nonmalignant indications.4-8
Though LT for HCC is a highly effective cure for early stage dis-
ease, guidance regarding tailored posttransplant management of this 
unique population to optimize outcomes is lacking. Given the het-
erogeneity of HCC burden and tumor biology seen in patients that 
present for transplantation, it is essential for transplant providers to 
consider the unique features of a given patient's HCC when devising 
their posttransplant management plan. This paper aims to compre-
hensively review the current literature on posttransplant manage-
ment of patients with HCC, as well as identify gaps in our current 
knowledge that are in urgent need of further investigation.
2  | HCC RECURRENCE: MAGNITUDE OF 
THE PROBLEM
Although LT provides an excellent treatment option for long-term 
survival in selected patients with HCC, posttransplant HCC recur-
rence is an important negative predictor of posttransplant sur-
vival. In the initial study by Mazzaferro and colleagues evaluating 
the role of LT in cirrhotic patients with small unresectable HCC, 
8% of patients experienced HCC recurrence by 4 years after LT.3 
Subsequently, studies focused on patients within Milan criteria using 
pretransplant data have described posttransplant recurrence in ap-
proximately 10%-16% of patients.9-11 A 2015 systematic review in-
cluding a heterogeneous group of 61 studies demonstrated a mean 
rate of HCC recurrence of 16% and mean time from transplant to 
HCC recurrence of 13 months (range 2-132 months).12 Of note, 
nearly 51% of LT recipients in this review were ultimately classi-
fied as beyond Milan based upon examination of explant pathology. 
Notably, as many centers worldwide transplant patients with HCC 
that are beyond Milan criteria, the magnitude of HCC recurrence 
may be larger than proposed by these estimates.
3  | PREDIC TION OF HCC RECURRENCE
Multiple tumor related factors have been identified to predict 
the risk of HCC recurrence after LT, and these factors have been 
incorporated in a number of proposed pre-LT and post-LT prognostic 
models (Tables 1 and 2).
3.1 | Well-established pretransplant factors 
predicting HCC recurrence
3.1.1 | Radiographic tumor burden
Traditionally, radiographic tumor diameter and number of tumor nod-
ules have been used as criteria determining eligibility for LT, based 
on the observation that these morphologic parameters are associated 
with microvascular invasion (MVI) and HCC recurrence after LT. The 
Milan criteria3 have been incorporated into the United Network for 
Organ Sharing/Organ Procurement and Transplantation Network 
(UNOS/OPTN) policy for priority listing with model end-stage liver 
disease (MELD)-exception for LT since 2002 (modified as UNOS T2 
criteria). Modest expansion of the upper limits of tumor burden, in-
cluding the University of California San Francisco (UCSF) criteria24,25 
and the “up-to-7” criteria,26 have resulted in survival only slightly 
below that using Milan criteria. Further expansion of tumor criteria 
would result in significantly reduced posttransplant survival, as illus-
trated in the “Metro-ticket” paradigm of “the further the distance, the 
higher the price.”26 The decision regarding expansion of transplant 
tumor criteria must be governed by the ability to achieve a minimal 
survival threshold to justify expansion and not cause harm to non-
HCC patients on the waiting list.3,27
A strategy combining tumor burden with assessment of re-
sponse to local regional therapy (LRT) over time as a marker of 
favorable tumor biology has gained broader acceptance. Patients 
who exhibit tumor progression despite LRT have significantly 
worse post-LT outcomes when compared to those who demon-
strate treatment response or stable disease following LRT.28-30 
Down-staging represents a structured approach that aims at 
merging tumor morphologic parameters with objective and 
sustained response to LRT31 as an additional risk stratification 
tool. This approach is supported by the observation that post-LT 
survival outcomes in those who have been successfully down-
staged to conventional Milan criteria and are not significant dif-
ferent than those who meet Milan criteria at presentation.31 In an 
effort to standardize criteria for down-staging of HCC prior to LT, 
OPTN/UNOS recently adopted the UCSF/Region 5 down-staging 
protocol with specific inclusion criteria31,32 as a new national pol-
icy for granting automatic MELD exception for LT. Initial tumor 
burden beyond these criteria have been suggested to have an ad-
verse impact on both the probability of successful down-staging33 
and worse post-LT survival.34 It has been suggested that there is 
a strong correlation between the initial tumor burden assessed 
by the sum of the largest tumor diameter and the probability of 
successful down-staging to within Milan criteria.33 Furthermore, 
extending the initial tumor burden beyond the current UNOS 
down-staging inclusion criteria is associated with a significantly 
worse 3-year post-LT survival in an analysis of UNOS data.34
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Despite advances in cross-sectional imaging over the last few de-
cades, radiographic understaging of HCC still occurs in up to 25%-
30% of patients.35-38 Furthermore, misdiagnosis has been reported 
in 11%-25% (no HCC found in explant).39,40 To reduce the misdiag-
nosis rate, a revised UNOS/OPTN imaging policy for HCC was im-
plemented, requiring structured reporting, standardized imaging 
TA B L E  1   Summary of proposed pretransplant selection models (selected)a
Pre-LT selection model Tumor burden Biomarker(s) Additional criteria
5-y post-LT overall 
survival AUROC
US National Policy13 Milan or down-staged to 
Milan
AFP >1000 ng/mL 
reduced to <500
 80%  
French AFP Model14 Size and number (lowest 
risk: largest tumor ≤3 cm 
and ≤3 tumors)
AFP (lowest risk: 
≤100 ng/mL)
 68% if risk score ≤2% vs 
47% if risk score >2
0.7
Metro-Ticket 2.015 Tumor number + size of 
largest tumor
AFP   0.72
TTV-AFP Model16 Total tumor volume ≤115 
cm3
AFP ≤400 ng/mL  75% (at 4 y) for those 





No upper limits  (1) Biopsy of largest 
tumor: poorly differen-
tiated tumors excluded
(2) No cancer-related 
symptoms
68% for those >Milan 
but within ETC
 
Pre-MORAL18 Largest tumor size (lowest 
risk: ≤3 cm)
AFP (lowest risk: 
<200 ng/mL)





HALT-HCC19 Hypotenuse between 
tumor number & largest 
tumor sizeb
lnAFP MELD-Na  0.61
NYCA Score20 Tumor number + size of 
largest tumor
AFP response to 
treatment
 Low-risk 75%, accepta-
ble-risk 62%, high-risk 
40%
0.73
AFP, alpha-fetoprotein; LT, liver transplantation; MELD, model end-stage liver disease; NLR, neutrophil/lymphocyte ratio; RFS, relapse-free survival.
aProposed criteria based on living donor liver transplant are not included. 
bBy Pythagorean Theorem (A2 + B2 = C2); eg, a patient with 3 lesions with largest 4 cm would receive tumor burden score of 5. 
TA B L E  2   Summary of proposed posttransplant prognostic models (selected)a
Post-LT 
prognostic model Tumor burden Biomarker(s)
Other histologic 
features 5-y recurrence risk/survival AUROC
RETREAT21 Sum of largest viable tumor 
diameter and number of 
viable tumor
AFP Vascular invasion 5-yr recurrence risk 2.9% for 











Based on Normogram 0.76




5-yr recurrence-free survival 
ranging from 97% in low-risk 
group to 22% in very high-risk 
group
0.87




5-yr recurrence risk 14.5% for 
risk score <4 and 51.5% for risk 
score ≥5
 
AFP, alpha-fetoprotein; LT, liver transplantation; NLR, neutrophil/lymphocyte ratio.
aProposed criteria based on living donor liver transplant are not included. 
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protocols for LT centers and equipment specifications for dynamic 
contrast-enhanced multiphase computed tomography (CT) or mag-
netic resonance imaging (MRI).41,42
3.1.2 | Alpha-fetoprotein
Growing evidence suggests alpha-fetoprotein (AFP) to be a power-
ful prognostic biomarker in LT.43 AFP has been included in virtually 
every prognostic model in LT for HCC (Tables 1 and 2), but there 
is no consensus on an AFP cut-off value to be applied as an exclu-
sion criterion for LT. AFP levels as low as 16 to 20 ng/mL have been 
associated with poor post-LT outcomes3,43 A much higher AFP 
level of >1000 ng/mL before LT is associated with particularly poor 
post-LT survival, regardless of the tumor burden.14,44 A new UNOS 
policy has recently been implemented, requiring those with an AFP 
>1000 ng/mL to show a decrease in AFP to <500 ng/mL with LRT 
before LT can be undertaken. This policy is supported by a recent 
analysis of UNOS data showing that a decrease in AFP from >1000 
to 101-499 ng/mL before LT, mostly as a result of LRT, would result 
in a greater than twofold reduction in post-LT mortality and an al-
most threefold reduction in HCC recurrence.45
Many other approaches in using AFP to refine LT selection cri-
teria have been explored. A multicenter French study incorporated 
a number of AFP thresholds within a prognostic score that included 
AFP, largest tumor diameter, and number of tumor nodules.14 The 
Metroticket version 2.0 presented a continuum of AFP in combina-
tion with the sum of the largest tumor diameter and number of tumor 
nodules to predict post-LT survival.15 A positive AFP slope resulting 
from rising AFP values over time also appears to correlate with a 
higher risk of post-LT HCC recurrence,30,46-49 but the AFP slope 
threshold that predicts worse post-LT outcomes has varied from one 
study to another. It has also been shown in several large series that 
pre-LT AFP response to LRT significantly affects recurrence.20,50 It 
is important to note that AFP is not entirely specific to HCC-related 
production and can be elevated in the setting of hepatic inflamma-
tion, including in the setting of viral hepatitis.
3.2 | Well-established explant features predicting 
HCC recurrence
3.2.1 | Microvascular invasion
The presence of MVI on explant is strongly associated with HCC re-
currence and reduced survival after LT51,52 (Table 2). The incidence 
of MVI is almost twice as high in tumors larger than 5 cm compared 
to smaller tumors.38,53-56 Patients with multiple tumors are 2 times 
more likely to have MVI as a solitary tumor.57 AFP >1000 ng/mL56 
and positive uptake on PET58 have also been associated with a 
greater likelihood of MVI. Nevertheless, the lack of a standardized 
histological definition of MVI creates heterogeneity across studies, 
and the presence or absence of MVI cannot be reliably determined 
prior to LT (45). Biopsy of the tumor has a very low sensitivity for 
MVI detection.59 A noninvasive approach involving a contrast-
enhanced computed tomography based biomarker derived from a 
HCC “venous invasion gene” gene expression signature, referred 
to as “radiogenomics,”59 has shown promise, but the usefulness of 
radiogenomics in LT candidates with early stage HCC requires fur-
ther study. Similarly, the creation of a radiographic-radiomic model 
using clinical and contrast-enhanced computed tomography factors 
to predict MVI for HCC may have an application for early stage HCC 
patients considering LT, though further research is needed.60
3.2.2 | Histological grade of tumor differentiation
Poorly differentiated tumor grade has been identified in many stud-
ies as an important risk factor for HCC recurrence after LT54,61,62 
(Table 2). Several groups have proposed using pre-LT biopsies of the 
largest tumor to exclude patients with poorly differentiated HCC 
from LT, while placing no restrictions in the upper limits in tumor bur-
den as long as there was no radiographic evidence of macro-vascular 
invasion. Based on this approach, the University of Padova group re-
ported a 5-year actuarial survival rate of 75% and a recurrence-free 
probability of 92%.63 Using the same approach but also excluding 
those with cancer-related symptoms and poor performance status, 
the University of Toronto reported a 5-year post-LT patient survival 
of 69% (vs 78% with Milan) and HCC recurrence probability of 30% 
(vs 13% with Milan).17 Poorly differentiated tumor grade and vascu-
lar invasion were found in the explant in 8% and 40% respectively. A 
major concern about liberalizing tumor burden and relying on biopsy 
assessment of tumor histologic grade is that the overall agreement 
of preoperative needle core biopsy with explant histopathology was 
poor according to one study, in which a significantly lower percent-
age of cases were identified as poorly differentiated tumor grade by 
biopsy compared to explant (15% vs 28%).56 In addition, in a more 
recent series, the correlation with explant pathology was poor and 
had no utility over Milan criteria alone in predicting post-LT recur-
rence.64 At present, given the limitations of histologic assessment 
noted in current available evidence, no guidelines support routine 
use of biopsy to help guide eligibility of transplant for those with 
HCC.
3.3 | Other potential predictors of HCC recurrence
3.3.1 | Other biomarkers
Aside from AFP, a number of serum biomarkers have been re-
ported to be associated with the risk of HCC recurrence, includ-
ing des-gamma-carboxyprothrombin (DCP),65-67 AFP-L3%, and 
absolute AFP-L3.65 Some studies have also suggested that inflam-
matory biomarkers, including neutrophil/lymphocyte ratio (NLR) 
and platelet/lymphocyte ratio, can predict tumor recurrence after 
LT.18,68 Nevertheless, other studies did not confirm the association 
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between these inflammatory biomarkers and outcome after LT for 
HCC mostly within Milan criteria.19,69 The role of these biomarkers 
in clinical practice, especially with respect to candidate selection for 
LT, has not yet been clearly defined.
Genomic biomarkers have the potential to discriminate HCC re-
currence risk. In one study, allelic imbalance in chromosome 9/18 
microsatellites was found to strongly correlate with recurrence in 
HCC beyond Milan criteria.70 In another study on patients with 
tumor beyond Milan criteria, the presence of progenitor cell mark-
ers (either CK19 or S2 signatures) had significantly greater HCC 
recurrence rate and lower survival than those without these gene 
signatures.71
3.3.2 | Positron emission tomography scan
Several studies have suggested that 18F-fluorodeoxygluclose posi-
tron emission tomography/CT (18F-FDG PET/CT) was a prognostic 
marker in LT for HCC, showing good correlation between 18F-FDG 
avid tumors and unfavorable histopathological tumor characteristics 
including microvascular invasion and poorly differentiated tumor 
grade.58,72,73 Nonuptake of tumor on 18F-FDG PET/CT may allow 
the use of liberal tumor size criteria in living donor LT according to 
studies from Korea and Japan.74,75
3.3.3 | Hepatitis C virus infection
Hepatitis C virus (HCV)-associated cirrhosis is a well-established 
risk factor for HCC, and antiviral treatment with viral eradication 
is associated with a significant decline in HCC risk overall. Recent 
reports, however, have raised concern that antiviral therapy with 
directly acting antivirals may lead to an unexpected increased risk 
of HCC recurrence after potentially curative therapy, including re-
section and ablation.76-78 This concern has not been supported by 
subsequent studies and pooled or meta-analyses.79-82 In addition, al-
though data on posttransplant recurrence specifically are limited, di-
rect-acting antiviral therapy has not been associated with increased 
post-LT recurrence risk.83 Thus antiviral treatment decisions should 
be made in the context of organ access and clinical characteristics 
of the patient,84 but should not be avoided specifically to prevent 
HCC recurrence.
3.3.4 | Donor characteristics
Several donor characteristics, including older donor age85,86 and 
nonlocal livers,86 have been implicated as risk factors for HCC recur-
rence following LT. These findings require confirmation. The effects 
of graft type (living donor vs deceased donor) on HCC recurrence 
after LT have yielded conflicting results. When comparing living 
donor LT and deceased donor LT in the post-MELD prioritization era, 
a meta-analysis showed no significant difference in HCC recurrence 
rates between these grafts.87 However, it should be emphasized that 
having a potential live donor at listing compared to not has been as-
sociated with increased survival for patients with HCC, likely related 
to a lower dropout rate and a shorter waiting period for LT.88 In one 
study, those receiving allografts donated after cardiac death did not 
experience a higher rate of recurrence compared to donation after 
brain death organs.89
3.4 | Prognostic models
Proposed models based on variables that are available before LT 
generally follow the principle of combining tumor morphologic 
parameters (diameter, number, or volume) with measures or sur-
rogates of tumor “biology” metrics (Table 1). They include AFP and 
other biomarkers (DCP, NLR). Pre-LT biopsy of the tumors has also 
been used to determine histologic grade of differentiation and to 
exclude poorly differentiated tumors for LT. Although these prog-
nostic models were intended to improve selection of candidates 
with good post-LT outcomes, the patient populations were highly 
heterogeneous and most of these prognostic models were based on 
retrospective data collection. Consequently, these models still re-
quire vigorous testing and prospective validation using well-defined 
criteria for the upper limits in tumor burden and specific thresholds 
for these biomarkers.
The post-LT prognostic models are based on explant tumor 
histopathologic characteristics, and they most commonly include 
measures of tumor burden, tumor grade of differentiation, and 
the presence or absence of vascular invasion (Table 2). The ma-
jority of these prognostic models also include AFP and/or other 
biomarkers. The post-LT prognostic models help identify candi-
dates at high risk for HCC recurrence and provide a reference for 
the expected incidence of HCC recurrence. These models are also 
helpful in the development of standardized post-LT surveillance 
strategies and the identification of the appropriate subgroups at 
sufficiently high risk for HCC recurrence to be considered for clin-
ical trials using neoadjuvant therapy to reduce the risk of HCC 
recurrence.
3.5 | Knowledge gaps
- AFP is currently the most widely utilized serum biomarker but 
there is no consensus on standardized cut-off values and/or 
dynamic changes in AFP levels to guide clinical decision making.
- Standardization of the definition of MVI is needed for both re-
porting and research purposes.
- Most other biomarkers remain investigational and have not yet 
been adopted in routine practice, and better biomarkers are still 
needed.
- Further exploration of the impact of specific liver-directed thera-
pies and the correlation with post-LT risk of HCC recurrence are 
needed.
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- Many pre- and post-LT prognostic models have been proposed 
but still require prospective independent validation. An ideal pre-
transplant model would lead to improved post-LT outcomes by 
incorporating surrogates of tumor “biology” metrics with conven-
tional morphologic parameters. Post-LT models would be useful in 
developing standardized post-LT surveillance strategies and iden-
tification of subgroups to be considered for future neoadjuvant 
therapy to reduce HCC recurrence.
4  | POST TR ANSPL ANT HCC 
SURVEILL ANCE
Surveillance may improve survival through access to earlier and 
perhaps curative treatment of recurrence.90-93 To be most effective, 
post-LT HCC surveillance should be done in the window of time 
that covers most recurrences, includes imaging of locations where 
recurrences are known to occur and with modalities that have good 
sensitivity and specificity. Unfortunately, although studies have 
looked at timing, risk factors, and characteristics of HCC recur-
rence, there remains a lack of data to guide serum and imaging tests 
and their frequency. Specifically, there are no trials to date studying 
surveillance protocols and their impact on post-LT outcomes.
4.1 | HCC recurrence patterns
Although the timing of posttransplant tumor recurrence is variable, 
peak HCC recurrence occurs within 2-3 years after transplant89,94 
(Table 3). Early HCC recurrence defined as within the first year of LT 
portends the worst prognosis.87,88,92 This could occur due to nonde-
tected extrahepatic metastases that may be present before LT and as 
a consequence of circulating HCC clones engrafting and growing in a 
target organ after LT. The plausible explanation for late HCC recur-
rence (within 2-5 years of LT) could be a second unknown hit that 
may lead to late engrafting of HCC cells that are less in number and 
remained latent for a long time during the post-LT period. HCC recur-
rence after >5 years of LT, though infrequent, has been described.85 
These data suggest that although surveillance should be most intense 
during the first 2 years, it should be maintained until at least 5 years 
post-LT for high-risk patients as longer time to recurrence is a predic-
tor for improved outcomes after treatment of recurrent HCC23,90,95,96
The pattern of HCC recurrence extends from hepatic to ex-
trahepatic and from single site recurrence to multiple site recur-
rence85,90,92,93,97-99 (Table 3). The most common extrahepatic sites 
are lungs and bones. However, HCC recurrence can also occur in 
adrenal glands, soft tissue (eg, local recurrence of biopsy tracks), 
peritoneum, and brain.
TA B L E  3   HCC recurrence time and location
Study and time period
Patients with 
recurrence






Roayaie et al 1998-2002 57/311 (18%) 12.3 (1.5-60.3) 9 (16%) 30 (53%) 18 (32%)
Cescon et al 1997-2009 34/283 (12%) 12 (1-118) 3 (9%) 7 (21%)
lung = 3
bone = 2 peritoneum = 2
24 (71%)
Escartin et al 1988-2005 28/184 (15%) Early <12 months = 5.7, 
late ≥12 months = 33.5
7 (25%) 21 (75%)
lung = 7
bone = 5, adrenal = 2  
peritoneum = 2 skin = 2
lymph node = 2 central  
nervous system (CNS) = 1
11 (39%)
Valdivieso et al 1996-2008 23/182 (9%) 23.4 2 (9%) 16 (70%)
lung = 9
bone = 3 adrenal =  
2 lymph node = 2
5 (22%)
Kornberg et al 1994-2007 16/60 (27%) 23 (4-58) 4 (25%) 12 (75%)
lung = 5
bone = 4
adrenal = 1 peritoneum = 1  
CNS = 1
 
Sharma et al 2002-2008 17/94 (18%) 25.2 6 (4%) 6 (4%)
lung = 1 adrenal = 3  
abdominal soft tissue = 2
11 (65%)
Mehta et al 2002-2012 84/721 (12%) 13 22 (26%) 84 (100%)
lung = 37, bone = 25,  
peritoneum = 22
21 (25%)
Fernandez-Sevilla et al 
1991-2013
70/493 (14.2%) 17 2 (2.8%) 51 (72.9%) 17 (24.3%)
Sapisochin et al 2000-2012 121/780 
(15.5%)
14 16 (13.2%) 63 (52.1%) 42 (34.7%)
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4.2 | Recommendations for post-LT surveillance
There are currently no clinical trial data to guide a recommenda-
tion for a specific surveillance protocol though expert groups have 
published consensus statements based upon the data available.12 
With recent advances in systemic treatment, the implementation 
of surveillance programs may result in earlier detection that may 
improve survival in patients with recurrence who are able to be 
treated with surgical, local, or systemic treatment. Therefore, all 
liver transplant recipients with HCC should be enrolled in a sur-
veillance program.
As there are no specific evidence-based risk stratification criteria 
that can be formally recommended, there is significant variation in 
surveillance practices between programs. In general, we recommend 
cross sectional imaging with either multiphase CT or multiphase MRI 
should be performed at least every 6 months for at least 2-3 years 
posttransplant as the majority of patients recur in this time. Many 
programs continue surveillance until 5 years posttransplant based 
upon the low likelihood or recurrence beyond this point; however, 
data on the best or most cost-effective length of surveillance are 
also not available to guide recommendations. Given the small 
amount of data for AFP in patients posttransplant, and the relatively 
low cost of this test, AFP level should be checked every 6 months for 
5 years.100,101 There are not enough data to validate use of other bio-
markers such as AFP-L3% or DCP in a routine surveillance program 
after LT for HCC.
Imaging for lung metastases with noncontrast CT chest should 
also be performed every 6 months in this period as well. Bone me-
tastases may also be a site of recurrence, but given the low sen-
sitivity of bone scan we do not recommend routine imaging with 
bone scan. Patients may present either with an elevation of alkaline 
phosphatase or with pain at the site of bone metastasis, and in case 
of these signs or symptoms further imaging may be performed at 
that time.
Risk-based screening has been proposed by several groups, in-
cluding by Mehta and colleagues recommending screening based on 
RETREAT score (no screening if RETREAT score = 0 due to estimated 
recurrence risk <3%, every 6 months for 2 years if score = 1-3, up to 
5 years for those if score = 4, and every 3 to 4 months for 2 years 
followed by every 6 months until year 5 if score ≥5).21,102 Although 
the RETREAT criteria could be considered for clinical use, these data 
must be prospectively validated and there are no published prospec-
tive studies of specific risk stratification-based surveillance strate-
gies. Ultimately risk-based screening would be desirable if it were 
shown to be safe and perhaps most cost effective.
4.3 | Knowledge gaps
• Prospective validation of imaging every 6 months as a surveillance 
strategy is needed in the liver transplant recipient population. In 
addition, data regarding the relative benefits of different lengths 
of surveillance are needed.
• Risk-stratified surveillance protocols must also be rigorously stud-
ied, perhaps including whether there are patients at sufficiently 
low risk that there is no benefit to surveillance.
• Whether post-LT surveillance improves HCC-related outcomes 
remains to be proven.
5  | STR ATEGIES FOR PRE VENTION OF 
HCC RECURRENCE
5.1 | Immunosuppression
The immunosuppression regimen of the patient is a possible factor 
in preventing HCC recurrence, as the immune system is a major de-
fense against cancer, either by attacking dysplastic cells themselves 
or by controlling viruses linked to cancer.103 Additionally, as the 
immunosuppression regimen can change over time, so can the sig-
nificance of HCC recurrence post-LT, as early recurrence may have 
a different biological behavior and identity compared to late HCC 
recurrence.104
Table 4 lists the different types of immunosuppression medica-
tions and the possible manner in which they can affect HCC recur-
rence post-LT, including the potential mechanisms involved. Though 
medication profiles may be strategically used to address HCC re-
currence, in practice multiple factors are weighted in formulating 
the optimal immunosuppression regimen for a specific patient such 
as consideration of side effects and comorbidities including kidney 
dysfunction.
A class of immunosuppression medications that appears to 
play a central role in most efforts to control HCC recurrence are 
the mammalian target of rapamycin (mTOR) inhibitors. Reducing 
calcineurin inhibitors (CNIs) and adding a mTOR inhibitor may re-
duce HCC recurrence, given antiproliferative properties against 
HCC.125 Specifically, mTOR involves two signaling pathways: 
mTOR complex1, which is responsible for cell proliferation based 
on regulatory signals from the immune system, and mTOR com-
plex 2, which affects cellular metabolism.126 The two main exist-
ing mTOR inhibitors are sirolimus (affecting complex 1 and 2) and 
everolimus (selective for complex 1). Sirolimus has demonstrated 
antiangiogenic activities linked to a decrease in production of vas-
cular endothelial growth factor (VEGF) and inhibited response of 
vascular endothelial cells to stimulation by VEGF.127,128 Data from 
small single-center retrospective studies, as well as two meta-anal-
yses, suggest that compared to CNI, use of sirolimus reduced the 
risk of HCC recurrence after LT118-123,129-131 Efficacy of this strat-
egy may vary depending on the stage of the initial disease or the 
presence of hepatitis C virus.132 The SiLVER study is a multicenter 
randomized controlled trial (RCT) seeking to obtain definitive an-
swers.124 In this study, though there appeared to be an advantage 
in the sirolimus group regarding improvement in recurrence-free 
survival in the first 3-5 years; this benefit is subsequently lost with 
further follow-up. Everolimus is approved for immunosuppression 
in LT recipients with low dose CNI and likely has similar effects as 
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sirolimus. However, available evidence is from small, single-cen-
ter studies that lack adequate power to make clear recommenda-
tions.133 Factors that result in reluctance to use mTOR inhibitors 
immediately post-LT include concern for increased risk of hepatic 
artery thrombosis and impaired wound healing.134,135 Therefore, 
the main impediment to widespread use of mTOR inhibitors for 
HCC recurrence prevention has been the lack of high-quality 
studies that demonstrate a benefit. Though mTOR inhibitors have 
shown some promise to reduce or prevent HCC recurrence in 
smaller studies, the highest quality data through the SILVER study 
does not show a benefit. At this time, there is a need for further 
well-designed multicenter studies to better delineate their use in 
the post-LT population. 
There are certain combination strategies of immunosuppression 
medications with a greater promise of success at minimizing risk of 
HCC recurrence. Medications such as steroids and CNIs possibly 
contribute to HCC recurrence, whereas others such as the mTOR 
inhibitors, and, to a lesser extent MMF, may have a beneficial effect. 
Though the optimal combination has yet to be found, an overall goal 
of reducing CNI with possible eventual complete withdrawal and 
avoidance of azathioprine and antithymocyte globulin is consistent 
with a strategy to minimize risk of HCC recurrence. As a counterbal-
ance, the addition of mTOR inhibitors with or without MMF, can help 
maintain a safe immunosuppression level to avoid rejection, while at 
the same time not endangering renal function and possibly prevent-
ing HCC recurrence. In the context of acute cellular rejection (ACR), 
the benefit of increased immunosuppression to attenuate alloreac-
tivity must be balanced against the risk of promoting oncogenesis. 
At present, no RCTs powered to detect differences in de novo tumor 
formation or HCC recurrence between ACR treatment strategies are 
available.
Though we seek an optimal medication strategy, the existence 
of multiple medication-, patient-, and disease-related variables make 
this challenging. Furthermore, a generalizable medication strategy 
may not be optimal. Rather, the biological behavior of HCC may 
prove to be better targeted by a patient-targeted approach, or oth-
erwise, a “personalized” strategy toward immunosuppression. The 
identification of noninvasive “biomarkers of tolerance” may help 
identify those patients where “safe” immunosuppression withdrawal 
may reduce the risk of HCC recurrence.
5.2 | Adjuvant systemic therapy
There is no evidence to support the use of adjuvant systemic chem-
otherapy to prevent post-LT HCC recurrence and this approach is 
not currently recommended. There is no evidence that adjuvant sys-
temic therapy using doxorubicin provides benefit in preventing HCC 
recurrence after LT.136 In an RCT of 58 patients, oxaliplatin-based 
adjuvant chemotherapy for patients with HCC beyond Milan crite-
ria showed improved 1- and 3-year overall survival in the adjuvant 
oxaliplatin group. However, there was no difference in the 3-year 
disease-free survival in both the groups.137
Licartin is a promising antineoplastic agent for adjuvant chemo-
therapy for patients with advanced HCC.138 It is an immune-radio-
conjugate containing metuximab, an antibody fragment targeting the 
HCC-associated antigen HAb18G/CD147, a member of CD147 family 
that is overexpressed in HCC and fibroblasts. Its expression is asso-
ciated with cancer cell progression and increased adhesion, invasion, 
and metastasis. Metuximab is conjugated to the radioisotope Iodine 
I.138 In an RCT of 66 HCC patients beyond Milan Criteria, the Licartin 
group received three doses every 28 days 3 weeks after LT and had 
a significantly lower HCC recurrence rate compared to the control 
group (27% vs 57%; P = .017).139 However, larger studies are needed.
The role of pre-emptive adjuvant therapy with sorafenib was 
initially considered promising but newer data demonstrate there 
is likely minimal added benefit. Most of these studies are limited 
to a small number of subjects, single-center studies, and case se-
ries.140-142 One of the largest retrospective studies examined the 
role of adjuvant sorafenib (25 patients) vs standard of care (20 
TA B L E  4   Immunosuppression and HCC recurrence
Type of immunosuppression medication Role in HCC recurrence after LT Proposed mechanism
Steroids105-108 Contributing possibly Reduce strength of immune inflammatory response, in-
hibit apoptosis and promote migration of malignant cells
Calcineurin inhibitors (CNIs)109-112 Contributing possibly High levels of CNIs oncologically detrimental; decreased 
HCC recurrence with lower trough levels
Antimetabolites113-115 Azathioprine possibly contributing; 
Mycophenolate mofetil (MMF) role 
unclear
Role of azathioprine as carcinogen; Although MMF has an 
antiangiogenesis and antiproliferative action it has not 
been shown to decrease HCC recurrence; however, it is 
used in order to decrease CNI levels
Induction agents116,117 Antithymocyte globulin (ATG) and 
Basiliximab role unclear by themselves
Helpful in reducing CNI levels, but because of their disap-
pearing effect on CD25 + cells, including tumor specific 
cytotoxic T cells, their overall effect is not clear
mTOR inhibitors (sirolimus and 
everolimus)118-124
Possibly decreasing HCC recurrence, 
although data not clear
Anticancer properties through mTOR inhibition, although 
when treatment is initiated may be critical regarding ef-
fectiveness; everolimus may stabilize HCC progression
HCC, hepatocellular carcinoma; LT, liver transplantation; mTOR, mammalian target of rapamycin.
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patients) in patients with advanced HCC on explant pathology. The 
authors concluded that the use of pre-emptive Sorafenib did not im-
prove recurrence free survival or overall survival.143 Similarly, data 
on the use of neoadjuvant sorafenib among patients with potentially 
curative resection or ablation therapy did not demonstrate a benefit 
in terms of recurrence.144
Immunotherapies have not been studied for prevention of 
posttransplant recurrence. Currently, a clinical trial examining the 
effects of nivolumab in patients with high risk of recurrence after 
curative resection or ablation is underway but does not include LT 
recipients.145
5.3 | Knowledge gaps
• The optimal immunosuppressive regimen to decrease the risk 
of HCC recurrence is currently unknown.
• Through their antiproliferative properties, mTOR inhibitors are 
the immunosuppresive agents believed to have the most prom-
ising role in preventing recurrence although data are limited 
and have not yet definitively demonstrated a benefit.
• Data on the use of adjuvant systemic chemotherapy in preventing 
HCC recurrence are needed.
• With the changing landscape of HCC and approval of new sys-
temic chemotherapeutic agents, future studies are warranted to 
characterize the efficacy and safety of these agents as adjuvant 
therapy in LT recipients.
6  | MANAGEMENT OF HCC RECURRENCE
HCC recurrences are usually asymptomatic and diagnosed as a result 
of surveillance imaging. Management is mainly focused at treatment 
of biopsy-proven HCC recurrences once they occur given strategies 
for prevention are limited.
6.1 | Surgical resection
Surgical resection for recurrent HCC has been shown to be an 
independent predictor of long-term survival if isolated to a single 
organ.90,92,146-148 In the largest single center experience, of 106 
total recurrences, 25 underwent surgical resection with overall 
better survival with this approach. In this series, a multivariable 
risk model was also constructed to predict postrecurrence sur-
vival.148 In a retrospective analysis, Valdivieso and colleagues 
identified 11/23 patients with HCC recurrence after LT who 
underwent surgical resection due to intrahepatic and extrahe-
patic disease; of these, eight patients obtained a R-0 resection.11 
Second recurrence was seen in 50% of the R-0 cases and all 3 
of the patients with R-1 resection. Despite this, overall recur-
rence-free survival was significantly higher in the R-0 cohort 
(32.3 months vs 6.9 months; P = .006) with a 5-year survival rate 
of 27% (vs 0% at 3 years in the other cohort). Similarly, Regalia 
and colleagues performed surgical resection of 7/21 patients 
with post-LT HCC recurrence with both intra- and extrahepatic 
disease.147 Patients who underwent surgical resection had a 57% 
survival rate at 4 years vs 14% survival rate in nonsurgical candi-
dates (P < .02). Finally, in a recent French study, 22/70 patients 
with recurrent HCC after LT who underwent surgical resection 
(2 intrahepatic and 20 extrahepatic) had a median survival of 
35 vs 15 months for nonresected patients (P < .001).92 In care-
fully selected patients with good functional status and limited 
disease, resection of isolated extrahepatic recurrent disease in 
regional lymph nodes, adrenals, and lungs have shown favorable 
survival.149-151
6.2 | Locoregional therapies
Data on liver directed therapy for the treatment of recurrent 
HCC after LT are lacking and limited to small case series. Zhai 
and colleagues examined the efficacy of microwave ablation 
(MWA) in the treatment of intrahepatic recurrence of HCC in 11 
LT recipients.152 Patients tolerated the procedure well with only 
three cases having tumor progression within 1-7 months after 
MWA. Survival rates at 1 and 2 years were 51.5% and 15.3% re-
spectively with an average survival time of 17.3 months. Ko and 
colleagues evaluated the efficacy of transcatheter arterial chem-
oembolization (TACE) in a cohort of 28 patients with recurrent 
HCC after living donor LT.153 Although tumor size was reduced 
by ≥25% in 19/28 patients, intra- or extrahepatic recurrence oc-
curred in 93% of patients during the 6-month follow-up period 
after the intervention. The 1-, 3- and 5- year survival rates were 
48%, 6%, and 0%, respectively. A single case report described 
the use of Yttrium-90 microspheres (Y-90) in a LT recipient with 
intrahepatic HCC recurrence 22 months after transplantation 
who failed both initial resection and adjuvant chemotherapy.154 
Follow-up imaging 2 months posttreatment showed tumor ne-
crosis and excellent treatment response but no long-term data 
were reported.
6.3 | Sorafenib and other RAF kinase inhibitors
The use of systemic chemotherapy in post-LT HCC recurrence 
is limited to small studies exploring the use of sorafenib in this 
setting. Treatment with sorafenib led to a median survival of 
12 months (range 1.45-20.1).116,127,155-158 In approximately 80% 
of these cases, an mTOR inhibitor was combined for immunosup-
pression. In a recent meta-analysis by Mancuso and colleagues, 
patients who received sorafenib for recurrent HCC after LT had 
an overall 1-year survival ranging from 18%-90% with a pooled 
estimate of 1 year survival at 63%.159 In a recent analysis of the 
US cohort of the GIDEON registry, the safety and tolerability of 
sorafenib was studied in patients with HCC recurrence who had 
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undergone LT or resection.160 Most adverse events occurred in 
the first 4 weeks of treatment and the incidence of adverse events 
resulting in discontinuation of drug were similar in both groups. 
There is no evidence of increased toxicity from sorafenib in the 
posttransplant setting compared to patients with primary HCC; 
however, the use of concomitant mTOR inhibitors can increase the 
rate of dose reduction or discontinuation due to severe side ef-
fects. There is also one multicenter retrospective series demon-
strating the safety of the use of regorafenib in LT recipients who 
failed to response to sorafenib.161
Data on the use of other systemic chemotherapy agents in this 
setting are also limited. The use of metronomic capecitabine in 38 
patients with post LT HCC recurrence showed a median survival of 
22 months compared to 7 months (P < .01) in patients who received 
best supportive care with an acceptable safety profile compared to 
sorafenib.162
6.4 | Immunotherapy
Despite the promise of checkpoint inhibitors in the treatment of 
several malignancies with excellent outcomes, the use of immuno-
therapy in transplant recipients is challenging due to the poten-
tially increased risk of allograft rejection and graft loss.163 Immune 
checkpoint inhibitors target cell death protein 1/programmed 
death ligand 1 (PD-1/PDL-1) or cytotoxic T-lymphocyte-associated 
antigen 4 (CTLA-4), all of which are important negative regulators 
of T cell immune function.164 Immune checkpoint inhibitors work 
by restarting an effective antitumor immune response, allowing 
immune system destruction of tumor cells. However, through this 
same mechanism, the immune system can also lose the ability 
to recognize self from non-self and thereby cause immune sys-
tem mediated adverse events similar to autoimmune diseases. 
Of importance in solid organ transplant recipients, the PD-1:PDL 
pathway plays an important role in regulating alloimmunity and 
transplant tolerance.165 Therefore, transplant recipients are at 
particular risk for allograft rejection when immune checkpoint in-
hibitors are used as cancer therapies. Theoretically, usage of such 
immunomodulatory agents in transplant recipients may promote 
the development of allograft injury, severe rejection, and even 
death.166
Nevertheless, HCC represents a promising target for anticancer 
immunotherapies such as immune checkpoint inhibitors targeting 
CTLA-4 and PD-1/PDL-1.166 Recently, two PD-1 checkpoint inhib-
itors, nivolumab and pembrolizumab, have been approved for ad-
vanced HCC as second line therapies. Both medications received 
conditional Food and Drug Administration approval based on limited 
phase II data, and unfortunately, recent phase III data showed pem-
brolizumab failed to improve progression-free or overall survival in 
patients with advanced HCC.
There have been multiple case reports in the literature of the 
use of CTLA-4 antibodies and PD-1/PDL-1 antibodies in patients 
after solid organ transplant. These reports have been in liver, 
kidney, heart, and corneal transplants, for several tumor types in-
cluding HCC, melanoma, and non-small cell lung cancer.166-172 There 
has only been one small case series from the Mayo Clinic on their 
single-center experience of PD-1 inhibitor therapy in seven liver 
transplant recipients, six with HCC and one with metastatic mela-
noma.170 Overall, the reported graft rejection rates in the literature 
have ranged from 25%-54%, with median time to graft rejection 
8-19 days after initiation of therapy.168,172 Several reports have de-
tailed successful treatment of graft rejection with steroids, myco-
phenolate mofetil, and antithymocyte globulin, but there have also 
been several reports of rapid graft failure and death from severe 
allograft rejection. Although there are reports of tumor response in 
transplant recipients with immune checkpoint inhibitors, it seems 
that the response rates are lower than that seen in nontransplant 
patients.168
Overall, there appears to be no clear association with time from 
transplant to treatment or particular immune suppression strate-
gies to predict or mitigate risk of rejection. Interestingly, there are 
emerging data that staining of liver allograft for PD-1 lymphocyte 
expression may be predictive, where lack of PD-1 staining lympho-
cytes in the allograft may be associated with a lower risk of rejec-
tion.170 However, until there are more robust clinical trials that allow 
prediction and clarification of the risk of graft rejection and loss in 
transplant recipients, the immune checkpoint inhibitors must be 
used with extreme caution in these patients.
6.5 | Knowledge gaps
• Despite availability of various treatment strategies, including the 
use of chemotherapeutic regimens, surgical resection, and liv-
er-directed therapy, long term recurrence free survival is currently 
rarely achieved and is an important area of further research.
• Data are limited regarding the use of immune checkpoint inhibi-
tors in this population, particularly given the potential increased 
risk of rejection. Given the lack of robust data or guidelines, fur-
ther studies should employ a multidisciplinary and multimodal ap-
proach tailored to each patient.
7  | CONCLUSIONS
As the incidence of HCC continues to rise, patients with HCC will 
be an increasingly large proportion of our transplant population. 
Although we have learned a significant amount about how to cure 
patients of HCC with transplant and risk stratify for recurrence, 
there remain many opportunities for improvement in our post-
transplant management. We therefore have provided a roadmap of 
knowledge gaps aimed at guiding the development of studies that 
will significantly advance posttransplant care of these patients, 
including in the areas of posttransplant surveillance, prophylactic 
measures including alteration of the standard immunosuppression 
regimen, and treatment of established HCC recurrence.
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